IL23R and inflammatory bowel disease: In addition, Jurgens et al. has examined the association of the IL-23R gene polymorphisms as a genetic predictor of infliximab responsiveness in UC patients and showed that UC patients carrying the IBD risk-increasing IL-23R polymorphisms were more likely to respond to infliximab than patients carrying the IBD risk-decreasing IL-23R polymorphisms (74.1% vs. 34.6%, P = 0.001), which suggests that IL-23R gene is related to treatment of UC patient [60].